Alex Delaney-Gesing 


S.K. Steven Houston III, MD, discusses retina innovations in use in his practice, including the NGENUITY 1.4 upgrade from Alcon, and adapting to ever-changing operating room spacing and set-up in the COVID-19 environment, in an interview with

 Sheryl Stevenson during the virtual 2020 American Society of Retina Specialists (ASRS) meeting.

Videos

S.K. Steven Houston III, MD, discusses retina innovations in use in his practice, including the NGENUITY 1.4 upgrade from Alcon, and adapting to ever-changing operating room spacing and set-up in the COVID-19 environment

ASRS 2020: How one surgeon is integrating recent retina advances in COVID-19

®' Sheryl Stevenson on the take-away points from his presentation on diabetic retinopathy progression in anti-VEGF versus FA implant during the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting, and how the topics from his talk may be applied day to day in retinal practice.


Caesar Luo, MD, shares the take-away points from his ASRS presentation, and how the topics from his talk may be applied day to day in retinal practice.



ASRS 2020: Diabetic retinopathy progression in anti-VEGF versus FA implant


Theresa Heah, MD, provides an update on AsclepiX’s AXT107, which is derived from a cryptic peptide within collagen IV that works by activating naturally existing, homeostatic mechanisms of angiogenesis, during the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting.

Theresa Heah, MD, provides an update on AsclepiX’s AXT107, which is derived from a cryptic peptide within collagen IV that works by activating naturally existing, homeostatic mechanisms of angiogenesis.

ASRS 2020: AsclepiX lead candidate holds potential for wet AMD, DME, RVO


Derek Kunimoto, MD, JD, focuses on Aviceda's technology, which will aim to target various immune system responses that contribute to pathology associated with dry AMD, in an interview with Sheryl Stevenson, 

group editorial director, during the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting.

Derek Kunimoto, MD, JD, focuses on Aviceda's technology, which will aim to target various immune system responses that contribute to pathology associated with dry AMD. 

Author | Alex Delaney-Gesing

Articles

ASRS 2020: How one surgeon is integrating recent retina advances in COVID-19

ASRS 2020: Diabetic retinopathy progression in anti-VEGF versus FA implant

ASRS 2020: AsclepiX lead candidate holds potential for wet AMD, DME, RVO

ASRS 2020: What Aviceda’s lead candidate AVD-104 may mean for dry AMD